RecruitingOBSERVATIONAL

GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial

This study is a registry, which means it's collecting information about adults (18 and over) in the UK who have acute lymphoblastic leukaemia (ALL) or certain related blood cancers. The aim is to understand more about how these conditions are diagnosed, which treatments are used, and how patients respond over time. This information helps doctors learn what works best and find ways to improve care in the future. You might be eligible if you have ALL, certain other leukaemias, or some types of non-Hodgkin's lymphoma and are being treated using standard ALL approaches. The study gathers details from your routine medical care, making it easier to contribute without major changes to your treatment plan.

At a glance

Status

Recruiting

Sponsor

Goethe University

Enrolment target

10,000

Start

01 Feb 2009

Estimated completion

01 Dec 2035

Acute Lymphoblastic Leukemia Leukemia Non-Hodgkin's Lymphoma

What is this study about?

This study is called the GMALL Registry, and it's created to help doctors and researchers better understand acute lymphoblastic leukaemia (ALL) in adults, as well as some similar blood cancers. Think of a registry like a large, organised library where medical information about a specific condition is gathered and stored. The main goal is to collect detailed information about how these conditions are diagnosed, the different treatments people receive, and how they recover over time.

By gathering this real-world information from many patients, researchers can see patterns and learn what works well, what doesn't, and what might need improvement. This is important because it can help guide decisions about new treatments and improve the quality of care for ALL patients in the future. It’s about making sure that the care people receive is as effective as possible.

It’s important to know that this isn't a new treatment study where you would receive an experimental drug. Instead, it's about collecting information from your standard care – the treatments you'd be receiving anyway. This means you won’t be asked to try new, unproven treatments as part of this study.

Key takeaways

This study helps improve future care for adults with specific blood cancers.
It collects information from your routine medical care, not experimental treatments.
Participation involves sharing medical data and perhaps existing tissue samples.
There are no extra appointments or medications involved for you.
Your contribution helps researchers learn more about leukaemia treatments.
You can stop participating at any time without affecting your medical care.

Who may be eligible?

This study is looking for adults aged 18 and older who have been diagnosed with certain types of blood cancers.

You might be able to take part if you have acute lymphoblastic leukaemia (ALL), including all its different forms. You could also be eligible if you have other specific types of leukaemia, such as NK cell lymphoma/leukaemia or biphenotypic acute leukaemia, as long as you are being treated with methods similar to those used for ALL.

Finally, some people with certain types of non-Hodgkin's lymphoma might also be able to join. This includes Burkitt lymphoma, B cell lymphoma, B- or T-lineage lymphoblastic lymphoma, and anaplastic large cell lymphoma, provided your treatment follows approaches typically used for B-ALL.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Have you been diagnosed with acute lymphoblastic leukaemia (ALL)?
Or do you have specific types of other leukaemia or non-Hodgkin's lymphoma?
Are you being treated with typical ALL-related protocols for your condition?

Answer every question to see your result.

What does participation involve?

Taking part in this study would generally involve allowing the study team to collect information from your routine medical records and possibly some tissue samples that are already being taken as part of your standard diagnostic and treatment procedures. This means there would be no extra hospital visits or special tests just for the study.

Your doctors would simply share de-identified information about your diagnosis, the treatments you receive (like chemotherapy or other medications), and how your condition progresses over time. You would continue to receive your medical care as normal from your own doctors.

There are no specific medications given as part of this study, as it's purely for data collection. The study would follow your health information for as long as you are receiving care for your condition, or until the registry research is complete, but it won't change how your care is delivered.

Potential risks and benefits

The main benefit of taking part is contributing to a greater understanding of acute lymphoblastic leukaemia and related cancers, which could help improve treatments and care for future patients. For you personally, there is no direct medical benefit or change to your treatment. The risks are very low, mainly related to the privacy of your information, but all data would be handled securely and confidentially. You are always free to withdraw your consent and stop participating at any time without affecting your medical care.

Locations (152)

Universitätsklinikum Graz
Verified postcode
Graz, Austria· Recruiting
LKH-Hochsteiermark Leoben
Verified postcode
Leoben, Austria· Recruiting
Hanusch-Krankenhaus Wien
Verified postcode
Vienna, Austria· Recruiting
University Hospital of Frankfurt (Main)
Verified postcode
Frankfurt am Main, Germany· Recruiting
Universitätsklinikum Aachen
Verified postcode
Aachen, Germany· Recruiting
Klinikum Altenburger Land
Verified postcode
Altenburg, Germany· Recruiting
Kreiskliniken Altötting
Verified postcode
Altötting, Germany· Recruiting
Klinikum Aschaffenburg
Verified postcode
Aschaffenburg, Germany· Recruiting
Klinikum Augsburg
Verified postcode
Augsburg, Germany· Recruiting
Helios Klinikum Bad Saarow
Verified postcode
Bad Saarow, Germany· Recruiting
Sozialstiftung Bamberg
Verified postcode
Bamberg, Germany· Recruiting
Klinikum Bayreuth
Verified postcode
Bayreuth, Germany· Recruiting

Common questions

What is a 'registry' study?

A registry study collects information from many patients about a specific illness, helping doctors learn more about how it's diagnosed, treated, and how people recover without changing their care.

Will I get new medicines or treatments in this study?

No, this study doesn't involve new medicines or treatments. It collects information about the care you're already receiving as part of your normal treatment plan.

How will my information be kept private?

All your personal details would be kept strictly confidential. The information shared with the study would typically be anonymised or coded so that it cannot be directly linked back to you.

Do I have to live in a specific place in the UK to join?

The study aims to collect information across the UK. You would generally be eligible if your hospital is participating in sharing data with the registry.

What happens if I change my mind after joining?

You can decide to stop being part of the study at any time, and you don't need to give a reason. This won't affect the medical care you receive in any way.

How to find out more

Nicola Gökbuget, Dr. med.

goekbuget@em.uni-frankfurt.de +496963016365 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.